Department of Nursing, Hubei Cancer Hospital, Wuhan 430079, Hubei, China.
Department of Chest Oncology, Hubei Cancer Hospital, Wuhan 430079, Hubei, China.
J Healthc Eng. 2021 Dec 13;2021:6801779. doi: 10.1155/2021/6801779. eCollection 2021.
To explore the application of evidence-based nursing intervention in the treatment of advanced squamous cell carcinoma of the lung by erlotinib combined with tegafur, gimeracil, and oteracil potassium (TS-1) and its influence on quality of life (QOL).
Clinical data of 92 patients with advanced squamous cell carcinoma of the lung treated with erlotinib and TS-1 in our hospital (January 2017-January 2021) were retrospectively analyzed. Forty-six patients receiving conventional nursing were set as the control group (CG), and other 46 patients receiving evidence-based nursing intervention additionally were set as the study group (SG). The clinical observation indexes of the two groups were compared and analyzed.
No obvious difference in general data between both groups ( > 0.05). According to EORTC QLQ-C30, compared with the CG, the scores of role function, physical function, social function, cognitive function, and emotional function in the SG were remarkably higher ( < 0.05). After intervention, scores of VAS of patients were obviously lower than those before intervention ( < 0.05), and scores of VAS in the SG after intervention were obviously lower than those in the CG ( < 0.05). After intervention, scores of SAS and SDS were lower than those before intervention, and those of the SG were obviously lower than those of the SG ( < 0.05). Compared with the CG, incidences of adverse reactions such as diarrhoea, nausea and vomiting, erythra, pressure sores, and leukopenia in the SG were obviously lower ( < 0.05). Compared with the CG, "very satisfied" and total satisfaction in the SG were obviously higher ( < 0.05).
Application of evidence-based nursing intervention in the treatment of advanced squamous cell carcinoma of the lung by erlotinib combined with TS-1 can help patients to relieve pain, improve their psychological state, reduce the incidence of adverse reactions, significantly improve the QOL, and also enhance the satisfaction of clinical nursing.
探讨循证护理干预在厄洛替尼联合替吉奥（TS-1）治疗晚期肺鳞癌中的应用及对生活质量（QOL）的影响。
回顾性分析我院 2017 年 1 月至 2021 年 1 月收治的厄洛替尼联合 TS-1 治疗的 92 例晚期肺鳞癌患者的临床资料。将接受常规护理的 46 例患者设为对照组（CG），另将加用循证护理干预的 46 例患者设为观察组（SG）。比较并分析两组患者的临床观察指标。
两组一般资料比较差异无统计学意义（>0.05）。与 CG 相比，SG 的角色功能、躯体功能、社会功能、认知功能和情绪功能评分均显著更高（<0.05）。干预后，患者的视觉模拟评分法（VAS）评分均明显低于干预前（<0.05），且 SG 的 VAS 评分明显低于 CG（<0.05）。干预后，两组的焦虑自评量表（SAS）和抑郁自评量表（SDS）评分均低于干预前，且 SG 的 SAS 和 SDS 评分明显低于 CG（<0.05）。与 CG 相比，SG 的腹泻、恶心呕吐、皮疹、压疮和白细胞减少等不良反应发生率明显更低（<0.05）。与 CG 相比，SG 的“非常满意”和总满意度明显更高（<0.05）。
在厄洛替尼联合 TS-1 治疗晚期肺鳞癌中应用循证护理干预，有助于减轻患者的疼痛，改善其心理状态，降低不良反应发生率，显著提高 QOL，还能提高临床护理满意度。
